Gilead Sciences, Inc.
About Gilead Sciences, Inc.’s 13F portfolio
Gilead Sciences, Inc. is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Gilead Sciences, Inc. reported $1.6B across 5 US-listed positions (). Its largest position is Arcus Biosciences Inc. (RCUS) at 59% of the reported book, and its ten biggest holdings make up 100% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NYSE: RCUS Arcus Biosciences Inc. | $15.76 −3.84% | 59% | 31.4M | $968.8M |
| 2 | NASDAQ: GLPG Lakefront Biotherapeutics | $28.02 −0.32% | 30% | 16.7M | $500.2M |
| 3 | NASDAQ: ASMB Assembly Biosciences Inc. | $22.39 −0.49% | 8.3% | 5.0M | $136.8M |
| 4 | NASDAQ: KYTX Kyverna Therapeutics Inc. | $4.48 −4.68% | 2.2% | 4.1M | $36.8M |
| 5 | NASDAQ: XLO Xilio Therapeutics Inc. | $7.63 +1.19% | 0.4% | 650K | $6.2M |
Showing the 5 largest positions reported in this 13F.
- Healthcare100%
Reading Gilead Sciences, Inc.’s 13F portfolio
Gilead Sciences, Inc.’s $1.6B 13F book is spread across 5 reported positions and is highly concentrated — its ten largest positions alone are 100% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are RCUS, GLPG, ASMB, KYTX and XLO, led by Arcus Biosciences Inc. (RCUS) at 59% of the portfolio. The heaviest sector exposure is Healthcare (100%).
What a 13F does and doesn’t reveal
A 13F captures only Gilead Sciences, Inc.’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Gilead Sciences, Inc. is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Gilead Sciences, Inc.'s profile on this page is built directly from those filings.
How current is the 13F data on Gilead Sciences, Inc.'s page?
It reflects Gilead Sciences, Inc.'s most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Gilead Sciences, Inc. files its next quarterly report, this page refreshes automatically.
Can I see Gilead Sciences, Inc.'s complete list of holdings?
This page highlights Gilead Sciences, Inc.'s largest positions rather than all 5 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Gilead Sciences, Inc.'s filings.
Does a 13F show everything Gilead Sciences, Inc. owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Gilead Sciences, Inc.'s book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Gilead Sciences, Inc. made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

